Nuclear medicine communications
-
The present study was performed for head-to-head comparison between 68Ga-prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) and 99mTc-PSMA whole-body and regional single-photon emission computed tomography (SPECT)/CT for the detection of prostate cancer metastases. ⋯ Whole-body 99mTc-PSMA combined with regional SPECT/CT could be a potential alternative to 68Ga-PSMA PET for the detection of the advanced stage metastatic prostate cancer and for response evaluation to PSMA-based targeted therapies.
-
To compare modified RECIST (mRECIST), EORTC criteria, and PERCIST for response evaluation and prognosis prediction in advanced malignant pleural mesothelioma (MPM) patients treated with chemotherapy. ⋯ EORTC and PERCIST are more accurate than mRECIST for evaluation of tumor response to chemotherapy and predicting prognosis in unresectable MPM patients.
-
The purpose of the current study was to investigate the diagnostic performance of F-18 fluorodeoxyglucose (FDG) PET or PET/computed tomography (PET/CT) for detection of post-transplant lymphoproliferative disorder (PTLD) through a systematic review and meta-analysis. ⋯ The current meta-analysis showed the high sensitivity and specificity of F-18 FDG PET or PET/CT for the detection of PTLD. At present, the literature regarding the use of F-18 FDG PET or PET/CT for the detection of PTLD remains limited; thus, further large multicenter studies would be necessary to substantiate the diagnostic accuracy of F-18 FDG PET or PET/CT for the diagnosis of PTLD.
-
Letter Case Reports
Asymptomatic COVID-19 positive patient suspected on FDG-PET/CT.